Artificial Intelligence in Drug Discovery Market by Offering (Services, Software), Technology (Context-Aware Processing, Machine Learning, Natural Language Processing), Process, Application, Therapeutic Area, End User - Global Forecast 2024-2030

Artificial Intelligence in Drug Discovery Market by Offering (Services, Software), Technology (Context-Aware Processing, Machine Learning, Natural Language Processing), Process, Application, Therapeutic Area, End User - Global Forecast 2024-2030

The Artificial Intelligence in Drug Discovery Market size was estimated at USD 1.08 billion in 2023 and expected to reach USD 1.35 billion in 2024, at a CAGR 27.10% to reach USD 5.81 billion by 2030.

Artificial Intelligence in drug discovery refers to the application of machine learning algorithms and AI systems in the process of discovering, designing, and optimizing new drug compounds. These AI models play a pivotal role in streamlining the traditionally complex and time-consuming drug discovery process, thus facilitating advancements in the field of medicine. The market growth is propelled by the growing burden of chronic diseases worldwide and the rising adoption of AI across biopharmaceutical companies for heightened precision, speed, and effectiveness in drug discovery. Moreover, the increasing need to manage the large data generated during preclinical studies drives market growth. The need for more skilled AI professionals in healthcare and the high costs associated with implementing AI is influencing growth limitation. The limited availability of data sets is a pivotal challenge curtailing the growth of AI in drug discovery. The opportunities are poised in fields related to novel drug discovery mechanisms and personalized medicine. Technological advancement in the burgeoning areas of AI research for drug development creates a potentiality for enhanced drug discovery, disease understanding, and patient-specific treatments.

Regional Insights

The U.S. stands at the forefront of integrating AI into drug discoveries, fuelled by an active start-up environment and robust governmental funding. Canada echoes this dedication with considerable investment in AI-driven discovery platforms. European countries, such as the UK, France, and Germany, are leveraging AI and data science to revolutionize drug discovery procedures, attributed to strategic collaboration between academic institutions and the pharmaceutical industry. With China, Japan, and India at the helm, Asia-Pacific offers compelling dynamics. China's massive AI investment, paired with Japan's excellence in pharmaceutical research, is fostering the adoption of AI in drug discovery. In India, governmental support and an expanding IT sector are moving towards AI in drug discoveries. The U.S., China, and EU lead in patent claims for AI drug discoveries, representing consistent innovation in their pharmaceutical industries.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Artificial Intelligence in Drug Discovery Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Demand to Control Drug Discovery Process and Reduce Cost
• Increasing Need to Manage the Large Data Generated During Preclinical Studies
• Increasing Adoption across Biopharmaceutical Companies

Market Restraints

• Unavailability of Skilled Professionals

Market Opportunities

• AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
• Increasingly Growing R&D Investments

Market Challenges

• Limited Availability of Data Sets

Market Segmentation Analysis

• Offering: AI Software propose a revolutionary approach to drug discovery
• Technology: Growing adoption of context-aware processing in personalized therapeutic
• Process: Significant augmentation in the drug discovery process with computational prowess and predictive capabilities
• Application: Growing usage of AI-designed small molecule drugs for human clinical trials.
• Therapeutic Area: Rising adoption of AI in the drug discovery for personalized cancer treatment.
• End User: Increasing use of AI in the drug discovery by pharmaceutical and biotechnology companies to accelerate their drug discovery process

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Artificial Intelligence in Drug Discovery Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Artificial Intelligence in Drug Discovery Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Merck entered into two new strategic collaborations in the field of drug discovery. These collaborations, with BenevolentAI and Exscientia, aim to utilize Artificial Intelligence (AI)-driven design and discovery capabilities to generate innovative drug candidates for clinical development in areas including oncology, neurology, and immunology.

Launch of Insilico’s Phase II Program Highlights Generative AI Momentum

Insilico Medicine has recently initiated Phase II clinical trials for a groundbreaking drug, INS018_055, developed using generative artificial intelligence in pharmaceuticals. This drug has received an Orphan Drug certificate from the FDA and aims to treat idiopathic pulmonary fibrosis (IPF). The utilization of artificial intelligence has significantly accelerated the drug development process for Insilico. Insilico has formed partnerships with several biopharma companies for AI-based drug development projects.

Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine

Google Cloud introduced two AI-powered solutions for the life sciences industry. These solutions aim to enhance drug discovery and precision medicine for biotechnology companies, pharmaceutical firms, and public sector organizations. The first solution, called the Target and Lead Identification Suite, helps researchers gain a better understanding of amino acids' function and predict protein structure. The second solution, known as the Multiomics Suite, expedites the discovery and interpretation of genomic data.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Artificial Intelligence in Drug Discovery Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Aria Pharmaceuticals, Inc., Atomwise, Inc., BenevolentAI Limited, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., Cyclica Inc., Deargen Inc., Deep Genomics Incorporated, Envisagenics, Inc., Euretos Services BV, Exscientia PLC, Insilico Medicine, Insitro, Inc., International Business Machines Corporation, InveniAI LLC, Microsoft Corporation, Novartis AG, NVIDIA Corporation, Oracle Corporation, Owkin, Inc., Verge Genomics Inc., and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Offering
• Services
• Software
• Technology
• Context-Aware Processing
• Machine Learning
• Natural Language Processing
• Process
• Candidate Selection & Validation
• Hit Identification & Prioritization
• Hit-to-lead Identification/ Lead generation
• Lead Optimization
• Target Identification & Selection
• Target Validation
• Application
• Biologics Design & Optimization
• Disease Identification & Assessment
• Safety, Toxicity, & Compliance Assessment
• Small Molecule Design & Optimization
• Vaccine Design & Optimization
• Therapeutic Area
• Cardiovascular Disease
• Immuno-Oncology
• Metabolic Diseases
• Neurodegenerative Diseases
• End User
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Research Centers and Academic & Government Institutes
• Region
• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year